文献速递乳腺US乳腺X线

筛查数字乳腺断层摄影召回的非钙化病灶诊断评估中超声优先策略的成本效果

Cost-Effectiveness of an Ultrasound-First Strategy in the Diagnostic Evaluation of Noncalcified Lesions Recalled From Screening Digital Breast Tomosynthesis.
PubMed 文献 · AJR Am J Roentgenol · 2024-07-31

本研究从美国医疗系统视角、40年时间跨度,用决策树分析比较超声优先与诊断性乳腺X线优先评估筛查数字乳腺断层摄影召回的非钙化病灶的成本效果。基础分析中超声优先策略总成本为17,672美元、诊断性乳腺X线优先为18,323美元,超声优先获得23.1309个质量调整生命年、诊断性乳腺X线优先为23.1306个,增量成本效果比为-2,170,000美元/质量调整生命年,增量净货币效益为681美元,概率敏感性分析中93.0%的迭代显示超声优先更优。结论认为超声优先(联合或不联合诊断性乳腺X线)比传统诊断性乳腺X线优先策略更具成本效果。

要点

  • 筛查数字乳腺断层摄影召回的非钙化病灶,超声优先策略总成本低于诊断性乳腺X线优先策略。
  • 超声优先策略增量成本效果比为-2,170,000美元/质量调整生命年,增量净货币效益681美元。
  • 概率敏感性分析中93.0%的迭代显示超声优先为更优策略。

核心结论

  • 超声优先(联合或不联合诊断性乳腺X线)比传统诊断性乳腺X线优先策略更具成本效果。
  • 该成本效果分析支持将超声作为评估数字乳腺断层摄影召回非钙化病灶主要方法的趋势。

研究设计与样本

  • 研究类型为决策树分析,从美国医疗系统视角、40年时间跨度比较超声优先与诊断性乳腺X线优先两种策略。
  • 分析采用已发表的单机构前瞻性数据的概率与患病率信息、文献衍生的诊断试验性能估计及 Medicare 允许的报销费率。
  • 健康状态以马尔可夫链模型表示,对每种策略估算总成本与效果(以质量调整生命年表示)。
  • 成本效果通过增量成本效果比与增量净货币效益评估,支付意愿阈值为每获得1个质量调整生命年100,000美元。
  • 确定性敏感性分析评估不同输入参数的影响,概率敏感性分析采用蒙特卡洛模拟评估参数联合不确定性的影响。

诊断标准与关键数值

  • 基础分析中,超声优先策略总成本为17,672美元,诊断性乳腺X线优先策略为18,323美元。
  • 基础分析中,超声优先策略获得23.1309个质量调整生命年,诊断性乳腺X线优先策略获得23.1306个。
  • 超声优先策略相对诊断性乳腺X线优先策略的增量成本效果比为-2,170,000美元/质量调整生命年,增量净货币效益为681美元。
  • 在每质量调整生命年100,000美元的支付意愿阈值下,超声优先被判定为更具成本效果。
  • 概率敏感性分析中,93.0%的迭代显示超声优先为更优策略。

临床应用与阅片要点

  • 确定性敏感性分析中,成本效果最重要的驱动因素为延迟诊断所致的效用损失,其次为超声与诊断性乳腺X线的相对敏感度。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

BACKGROUND. Ultrasound may be sufficient in the diagnostic evaluation of many noncalcified lesions recalled from screening digital breast tomosynthesis (DBT). In some scenarios, omission of diagnostic mammography can save health care costs. OBJECTIVE. The purpose of this study was to evaluate the cost-effectiveness of a strategy of performing ultrasound first versus diagnostic mammography first in the diagnostic evaluation of noncalcified lesions recalled from screening DBT. METHODS. Decision tree analysis was performed to compare ultrasound first versus diagnostic mammography first in the diagnostic evaluation of DBT-recalled noncalcified lesions from a U.S. health care system perspective with a 40-year horizon. The analysis used probabilities and prevalence information from published single-institution prospective data, additional literature-derived estimates of diagnostic test performance, and Medicare-allowable reimbursement rates. Health states were represented in a Markov chain model. For each strategy, the total cost and effectiveness (expressed in quality-adjusted life-years [QALYs]) were estimated. Cost-effectiveness was assessed through incremental cost-effectiveness ratios (ICERs) and incremental net monetary benefit, with use of a willingness-to-pay (WTP) threshold of US$100,000 per QALY gained. Deterministic sensitivity analyses were performed to estimate the impact of different input parameters, and probabilistic sensitivity analysis with Monte Carlo simulations was conducted to estimate the impact of combined uncertainty across parameters. RESULTS. In the base-case scenario, for diagnostic evaluation of DBT-recalled noncalcified lesions, a strategy of performing ultrasound first versus diagnostic mammography first resulted in more cost savings (total cost, US$17,672 vs US$18,323) and greater cost-effectiveness (QALYs, 23.1309 vs 23.1306) over the 40-year horizon. The ultrasound-first strategy resulted in an ICER of -2,170,000 (expressed as U.S. dollars per QALY) and an incremental net monetary benefit of US$681 versus the diagnostic mammography-first strategy. Therefore, performing ultrasound first was deemed the more cost-effective strategy at the WTP threshold. In deterministic sensitivity analyses, the most important driver of cost-effectiveness was lost utility from delayed diagnosis, followed by the relative sensitivities of ultrasound and diagnostic mammography. In probabilistic sensitivity analysis, ultrasound first was the better strategy in 93.0% of iterations. CONCLUSION. A strategy of performing ultrasound first, with or without diagnostic mammography, is more cost-effective than a traditional strategy of conducting diagnostic mammography first. CLINICAL IMPACT. This cost-effectiveness analysis supports the growing prioritization of ultrasound as the primary method for evaluating DBT-recalled noncalcified lesions.

来源:AJR Am J Roentgenol,查看原文。版权归原作者所有。

引用

  1. Ozcan BB, Xi Y, Dogan BE, et al. Cost-Effectiveness of an Ultrasound-First Strategy in the Diagnostic Evaluation of Noncalcified Lesions Recalled From Screening Digital Breast Tomosynthesis. AJR Am J Roentgenol. 2024. PMID: 39082850. doi:10.2214/AJR.24.31422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。